NCT05722782 Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics
| NCT ID | NCT05722782 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Monastir |
| Condition | Renal Colic |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 500 participants in total. It began in 2023-07-01 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Treatment with NSAI in renal colics has not been well investigated and there is no clear recommendations regarding this subject. The aim of this study is to determine if an oral NSAI treatment is beneficial in patients discharged for the emergency department after the first line treatment of a renal colic investigating the reccurence of pain, the reconsultation rates and the admissions.
Eligibility Criteria
Inclusion Criteria: * Over 18 years old * Consenting to participate in the study * Patients treated in the ED for RC * No contraindications of NSAI or paracetamol treatment Exclusion Criteria: * Contraindication of NSAI treatment * Patients non reachable by telephone call * Patients that did not receive or use the treatment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05722782 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Colic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05722782 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05722782 currently recruiting?
Yes, NCT05722782 is actively recruiting participants. Contact the research team at semir.nouira@rns.tn for enrollment information.
Where is the NCT05722782 trial being conducted?
This trial is being conducted at Monastir, Tunisia.
Who is sponsoring the NCT05722782 clinical trial?
NCT05722782 is sponsored by University of Monastir. The trial plans to enroll 500 participants.